Consumer Defensive · Beverages - Wineries & Distilleries · Synthos Deep Dive · 2026-07-03
| Verdict | Hold — systematic Synthos tier |
| Price (2026-07-02) | $26.15 · market cap ~$12.2B |
| Synthos scores (0–10) | Downside Risk 5 · Growth Quality 3 · Exponential Potential 1 |
| Synthos fair value (base case) | ~$28 → +7% · full range $21 (bear) – $39 (bull) |
| Street consensus | No numeric price target on file; grades consensus = Hold (0 Strong Buy · 5 Buy · 24 Hold · 7 Sell) — context, not our anchor |
| Valuation | 17.2× trailing EPS · ~15× FY27E · ~14× FY30E · EV/S 3.6× · EV/EBITDA 13.3× |
| Exponential Potential | 1/10 · Very Low — ~4% forward revenue CAGR, EPS declined in FY26, growth flat-to-decelerating; a mature staple, not an exponential |
| Technicals | Downtrend — $26.15, −16% off the 52-wk high, below 50/200-DMA, RSI 46, −6% 12-mo vs SPY +21% |
| Conviction | Low — 0 expert voices, 0 KB claims; call rests entirely on fundamentals + quant |
| Position sizing | Income/defensive satellite only, ~1–2% if owned at all — for the yield, not the growth |
| Next catalyst | 2026-08-27 Q1'27 earnings (Street EPS $0.37, revenue ~$918M) |
| Single biggest risk | A structurally softening spirits market (especially US whiskey + tequila) with no offsetting growth engine |
One-line thesis. Brown-Forman owns one of the best brands in beverage alcohol (Jack Daniel's) and a 42-year dividend-increase streak, but FY26 sales fell 1% and EPS fell 17%, management guides FY27 organic operating income down 3–5%, and the stock — while not expensive at ~17× — offers no growth catalyst; it is a quality income name to watch, not a compounder to chase.
Brown-Forman is the company behind Jack Daniel's whiskey — plus Woodford Reserve, Herradura and el Jimador tequila, and a growing line of pre-mixed canned cocktails. It has paid a dividend every quarter for 82 straight years and raised it for 42 years running, which tells you this is a steady, conservative, old-money business.
The problem: people are drinking a little less, especially in the US, and the whiskey and tequila categories have gone soft. So sales actually shrank last year and profit fell. The stock isn't wildly expensive — you're paying about 17 dollars for every dollar of yearly profit, which is fair — but there's no obvious reason for it to jump, because the business itself isn't growing right now. Our verdict is Watch: a fine, safe dividend-payer to keep an eye on, but not something to rush into for big gains.
Here's what our three scores mean in everyday terms:
The one big worry: fewer people are drinking spirits, and Brown-Forman doesn't have a fast-growing new product big enough to make up for it.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 46.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = BF-B · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Brown-Forman (NYSE: BF-B) is a ~155-year-old, family-controlled (Brown family) global spirits maker headquartered in Louisville, Kentucky. Its fiscal year ends April 30. The crown jewel is the Jack Daniel's family of Tennessee whiskeys; the portfolio also includes Woodford Reserve, Old Forester, Herradura and el Jimador tequila, New Mix (a fast-growing Mexican RTD), Gin Mare, Diplomático rum, and Chambord. The company sells through independent distributors and, in control states, state governments.
It is a member of the S&P 500 Dividend Aristocrats — 82 consecutive years of quarterly dividends and 42 consecutive years of increases.
Revenue mix (FY2026, from filings):
The strategic story management keeps returning to (see §9) is a US route-to-market transformation (changing distributor terms), a cost-restructuring program (announced Jan 2025), and innovation — chiefly Jack Daniel's Tennessee Blackberry and the New Mix RTD line — to offset a declining core.
There is no expert coverage of Brown-Forman in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No independent voice we track — bullish or bearish — has published a traceable claim on this name.
That is itself a signal: the panels Synthos ingests skew toward technology, AI, biotech, and high-growth compounders, and a mature consumer-staples spirits maker simply does not come up. We will not manufacture conviction we do not have. Everything below is therefore driven by the fundamentals (FMP filings), the analyst-estimate consensus, management's own guidance (half-weighted), and quant — not by expert conviction. Treat the verdict accordingly: it is a disciplined read of the numbers, not a high-conviction call backed by a panel.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Net-debt/EBITDA 1.75×, beta 0.34, a 3.5% aristocrat dividend and 60.5% gross margin cushion the downside — but the top line is shrinking, the category is softening, tariffs/tequila are a drag, and the stock has a −68% historical peak-to-trough drawdown. Cheap-ish (17×) limits the de-rating risk. |
| Growth Quality | 3 · Weak | 18% ROE and 60.5% gross margin are genuinely high-quality, but FY26 revenue fell 1% and EPS fell 17%; forward revenue CAGR is only ~4% and EPS ~6% off a depressed base. Profitability is good; growth is not. |
| Exponential Potential | 1 · Very Low | Mature, whiskey-concentrated staple in a secularly softening category; growth is flat-to-negative with no acceleration and a $12B cap in a slow TAM. Nothing here points to a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Restructuring + US distributor changes take hold, RTD (New Mix, +33% organic) and emerging markets re-accelerate the top line to low-single-digit growth; FY27E EPS recovers to ~$1.80 and the market re-rates a stabilizing aristocrat to ~22×. | ~$39 (+49%) |
| Base (our anchor) | FY27 plays out roughly as guided — organic sales ~flat, operating income down low-single-digits — then a slow recovery; FY27E EPS ~$1.70, a durable but low-growth aristocrat earns a ~16× multiple. | ~$28 (+7%) |
| Bear | The spirits down-cycle deepens, US tariffs and Canadian delisting persist, tequila keeps sliding; FY27E EPS slips toward ~$1.55 and the multiple de-rates to ~14× as growth stays absent. | ~$21 (−20%) |
Synthos fair value = the base case, ~$28 (+7%), with the full $21–$39 span as the honest range. There is no numeric Street price-target on file; the analyst grades consensus is Hold (5 Buy / 24 Hold / 7 Sell), which squares with our Watch. This is a tracked call — the Forecaster Scorecard grades it once it matures. The modest ~7% base-case upside plus a 3.5% dividend is a total-return-ish proposition, not a capital-appreciation thesis.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BF-B is neither right now — it is a high-quality but currently shrinking staple:
Exponential Potential: Very Low (1/10). Own BF-B, if at all, for the dividend and brand durability, never for growth. This honest framing is why it lands in Watch, not any Buy tier.
BF-B is not expensive on trailing numbers (17.2× EPS, 3.6× EV/sales, 13.3× EV/EBITDA, ~7.3% FCF yield, 3.5% dividend yield) — well below its own historical premium (this stock has traded 25–35× for much of the past decade). The catch is why it's cheaper: there is almost no earnings growth to discount. On consensus, forward P/E is ~15× (FY27E $1.70) easing to ~14× (FY30E $1.93) — the multiple barely compresses because EPS barely grows. FMP's letter rating is A- (quality) but flags a full price-to-book (~3.0×). A reverse read: at ~17× trailing with flat-to-low-single-digit growth, the stock is priced roughly fairly for a stable aristocrat — cheap enough to limit downside, not cheap enough to be a value bargain, and lacking the growth to be a growth buy. Street targets (context): no numeric consensus target on file; the grades split (5 Buy / 24 Hold / 7 Sell) reads Hold. Our $28 base-case FV (+7%) sits modestly above the current price — a hold-for-the-yield, not a table-pound.
Brown-Forman's moat is brand and heritage: Jack Daniel's is one of the most valuable spirits trademarks in the world, aged-whiskey inventory (2–8 years) is a genuine barrier (598 days of inventory outstanding — a working-capital cost and a moat), and family control (Brown family voting shares) gives long-horizon stability. The weakness is the flip side of concentration: ~74% of sales are whiskey, so a soft US whiskey cycle hits disproportionately, and tequila (Herradura −10% organic) is also sliding.
Peer set (FMP-supplied; note it is a broad consumer-staples group, not pure spirits comps): Molson Coors (TAP) $7.5B, Coca-Cola Consolidated (COKE) $15.4B, Clorox (CLX) $11.8B, Hormel (HRL) $13.8B, J.M. Smucker (SJM) $12.4B, Campbell (CPB) $7.0B, plus grocers/distributors (ACI, BJ, PFGC). The truest public comps (Diageo, Pernod Ricard, Constellation) aren't in this list; against them BF-B carries a premium brand and margin profile but the same category headwind. Relative to the staples peers shown, BF-B has a higher gross margin (60.5%) and stronger brand equity, but weaker current growth.
- Organic net sales: approximately flat.
- Organic operating income: decline of 3% to 5%.
- Effective tax rate: ~20–22%.
- Capex: $60–70M (down sharply — a lever behind rising FCF).
- CEO Lawson Whiting: finished FY26 "ahead of our expectations," expects "continued market volatility and a challenging cost cycle in the year ahead," leaning on the restructuring program (announced Jan 2025), the US route-to-market transformation, and innovation (Jack Daniel's Tennessee Blackberry, New Mix RTD). Read honestly: management is guiding to another down-ish year on operating income — the numbers, not the tone, are the signal.
Thesis tripwires (what would change the call): two more quarters of organic-sales decline (bearish); or, on the upside, a return to sustained low-single-digit organic growth plus margin recovery (would push toward Buy — Tactical); a dividend-growth pause would be a serious red flag.
Watch. Brown-Forman is a genuinely high-quality, family-controlled dividend aristocrat with a fortress brand (Jack Daniel's), a 60.5% gross margin, rising free cash flow (+$462M to $893M in FY26), and a fair-ish ~17× multiple. But the top line shrank in FY26 (revenue −1%, EPS −17%), management guides FY27 organic operating income down 3–5%, the chart is in a relative-weakness downtrend, and there is no expert conviction and no growth catalyst to underwrite an upgrade. The base case is ~$28 (+7%) plus a 3.5% dividend — a respectable income outcome, not a compelling appreciation one.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $26.15.